ImmuCell Corporation (ICCC)vsRoyalty Pharma Plc (RPRX)
ICCC
ImmuCell Corporation
$9.61
-2.63%
HEALTHCARE · Cap: $86.94M
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 8053% more annual revenue ($2.44B vs $29.93M). RPRX leads profitability with a 33.9% profit margin vs -1.8%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
ICCC
Hold44
out of 100
Grade: D
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.5%
Fair Value
$17.77
Current Price
$9.61
$8.16 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 28.4% year-over-year
Earnings expanding 31.3% YoY
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -1.9% — below average capital efficiency
Currently unprofitable
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ICCC profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
ICCC carries more volatility with a beta of 0.51 — expect wider price swings.
ICCC is growing revenue faster at 28.4% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 44/100), backed by strong 33.9% margins and 11.0% revenue growth. ICCC offers better value entry with a 63.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?